Jounce Therapeutics, Inc. 4/A SEC Filings

Filed On	Filing
17 Mar 2022	Form 4/A: Cole Hugh M, Chief Business Officer Granted 85,000 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Tepper Robert I, Director Granted 15,700 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Pfeffer Cary, Director Granted 15,700 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Karsen Perry A, Director Granted 15,700 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Kamen Robert, Director Granted 15,700 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Iannone Robert, Director Granted 7,850 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Higgons John Duncan, Director Granted 15,700 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Duncan Barbara Gayle, Director Granted 15,700 Stock Option (Right to Buy)
02 Jul 2020	Form 4/A: Diaz Luis, Director Granted 15,700 Stock Option (Right to Buy)

Comments